Globus Medical (MEX:GMED) Cash And Cash Equivalents : MXN5,876 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Globus Medical Cash And Cash Equivalents?

Globus Medical's quarterly cash and cash equivalents increased from Sep. 2023 (MXN4,870.67 Mil) to Dec. 2023 (MXN7,931.93 Mil) but then stayed the same from Dec. 2023 (MXN7,931.93 Mil) to Mar. 2024 (MXN5,876.10 Mil).

Globus Medical's annual cash and cash equivalents declined from Dec. 2021 (MXN3,960.62 Mil) to Dec. 2022 (MXN2,933.49 Mil) but then increased from Dec. 2022 (MXN2,933.49 Mil) to Dec. 2023 (MXN7,931.93 Mil).

Globus Medical Cash And Cash Equivalents Historical Data

The historical data trend for Globus Medical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Globus Medical Cash And Cash Equivalents Chart

Globus Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

3,691.36

4,762.09

3,960.62

2,933.49

7,931.93

Globus Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															3,923.77	5,253.78	4,870.67	7,931.93	5,876.10

Globus Medical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Globus Medical (MEX:GMED) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Globus Medical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Globus Medical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Globus Medical (MEX:GMED) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Globus Medical Inc (MEX:GMED) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

GMED:USA GM0N:Germany

Address

2560 General Armistead Avenue, Audubon, PA, USA, 19403

Website

https://www.globusmedical.com

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.